This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Pritam Kumar Saini,
- Student, Department Of Life Science- Botany, Raj Rishi Govt. College Alwar, Rajasthan, India
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_128857’);});Edit Abstract & Keyword
Gene therapy is a medical approach that focuses on altering or adjusting an individual’s genes to treat or prevent illnesses. The aim is to repair faulty genes or insert new ones into the body to combat diseases. Gene therapy can involve directly introducing modified or new genes into a patient’s cells or altering the genes already present in the patient’s body. This approach shows potential for treating a range of conditions, including genetic disorders like cystic fibrosis and sickle cell anemia, as well as certain forms of cancer. Although gene therapy has shown promise in clinical trials, challenges such as delivery methods, immune responses, and ethical considerations remain significant obstacles to its widespread use.
Modern medicine has witnessed transformative advancements, particularly in the field of gene therapy, a cutting-edge approach aimed at treating or potentially curing genetic disorders at their source. Unlike traditional treatments that focus on managing symptoms, gene therapy targets the root cause of disease by correcting or modifying defective genes within a patient’s cells.
Techniques such as viral vector delivery, CRISPR-Cas9, and RNA-based therapies enable precise alterations in the genetic code, offering hope for inherited disorders, cancers, and even infectious diseases. Recent clinical successes, including treatments for spinal muscular atrophy, hemophilia, and certain forms of blindness, highlight gene therapy’s potential to reshape therapeutic approaches. Despite these advancements, significant challenges persist in guaranteeing the safety, effectiveness, and worldwide accessibility of gene therapies. Issues such as immune responses to vectors, ethical concerns, high treatment costs, and regulatory complexities pose significant obstacles. However, ongoing research and advances in genome-editing technology, vector design, and delivery systems continue to enhance the safety and scope of gene therapy, paving the way for broader applications in modern medicine and a new era of personalized, precision healthcare.
Keywords: Gene editing, CRISPR-Cas9, Genetic disorders, Gene delivery, Adenovirus vectors, Lentivirus vectors, Somatic gene therapy
[This article belongs to International Journal of Genetic Modifications and Recombinations (ijgmr)]
Pritam Kumar Saini. Gene Therapy in Modern Medicine: Promises and Challenge in Treating Genetic Diseases. International Journal of Genetic Modifications and Recombinations. 2024; 02(02):-.
Pritam Kumar Saini. Gene Therapy in Modern Medicine: Promises and Challenge in Treating Genetic Diseases. International Journal of Genetic Modifications and Recombinations. 2024; 02(02):-. Available from: https://journals.stmjournals.com/ijgmr/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_128857’);});Edit
1. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-β/Smad and p38 mitogen-activated protein kinase signaling pathways. Human gene therapy. 2009 Oct 1;20(10):1190-200.
2. Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, Torre-Amione G, Youker KA. Decorin-mediated transforming growth factor-β inhibition ameliorates adverse cardiac remodeling. The Journal of heart and lung transplantation. 2007 Jan 1;26(1):34-40.
3. Li L, Okada H, Takemura G, Kosai KI, Kanamori H, Esaki M, Takahashi T, Goto K, Tsujimoto A, Maruyama R, Kawamura I. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. American Journal of Physiology-Heart and Circulatory Physiology. 2009 Oct;297(4):H1504-13.
4. Somia N, Verma IM. Gene therapy: trials and tribulations. Nature Reviews Genetics. 2000 Nov 1;1(2):91-9.
5. Niewöhner J, Tannert C, editors. Gene therapy: prospective technology assessment in its societal context. Elsevier; 2011 Aug 19
6. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. The journal of gene medicine. 2018 May;20(5):e3015.
7. Capone F, Nappi F, Galli MC. Gene therapy clinical trials: past, present and future. InSecond generation cell and gene-based therapies 2020 Jan 1 (pp. 285-301). Academic Press.
8. Arjmand B, Larijani B, Sheikh Hosseini M, Payab M, Gilany K, Goodarzi P, Parhizkar Roudsari P, Amanollahi Baharvand M, Hoseini Mohammadi NS. The horizon of gene therapy in modern medicine: advances and challenges. Cell Biology and Translational Medicine, Volume 8: Stem Cells in Regenerative Medicine. 2020:33-64.
9. Adi-Dako O, Kumadoh D, Pathak YV, Gyamerah NK. Overview of Development of Gene Therapy. InGene Delivery Systems 2022 Jul 1 (pp. 1-20).
10. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature medicine. 2001 Jan;7(1):33-40.
| Volume | 02 |
| Issue | 02 |
| Received | 09/11/2024 |
| Accepted | 28/11/2024 |
| Published | 24/12/2024 |